Filing Details

Accession Number:
0000899243-18-009413
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-04 13:33:53
Reporting Period:
2018-04-02
Accepted Time:
2018-04-04 13:33:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1661998 Homology Medicines Inc. FIXX () 0331
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1021944 Ltd (Private) Holdings Temasek 60B Orchard Road #06-18
Tower 2, The Atrium@Orchard
Singapore U0 238891
No No Yes No
1379348 Ltd Pte Management Fullerton 60B Orchard Road #06-18
Tower 2, The Atrium@Orchard
Singapore U0 238891
No No Yes No
1379349 Ltd Private Sciences Life Temasek 60B Orchard Road #06-18
Tower 2, The Atrium@Orchard
Singapore U0 238891
No No Yes No
1379350 Ltd Pte Investments V-Sciences 60B Orchard Road #06-18
Tower 2, The Atrium@Orchard
Singapore U0 238891
No No Yes No
1673754 Ltd. Pte. Beta Tls 60B Orchard Road #06-18
Tower 2, The Atrium@Orchard
Singapore U0 238891
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-04-02 1,605,681 $0.00 1,605,681 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-04-02 989,612 $0.00 2,595,293 No 4 C Indirect See footnote
Common Stock Acquisiton 2018-04-02 625,000 $16.00 3,220,293 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2018-04-02 1,605,681 $0.00 1,605,681 $0.00
Common Stock Series B Preferred Stock Disposition 2018-04-02 989,612 $0.00 989,612 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.
  2. The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.
  3. Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.
  4. Consists of 989,612 shares of Common Stock held of record by TLS Beta.
  5. Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.
  6. TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.